S. Barry Eiden, OD, FAAO, FSLS

Barry Eiden, OD, FAAO, FSLS, sits down with Optometry Times to highlight the importance of staying up-to-date with technology in the development of treatment and diagnosis of keratoconus and what's to come at this year's IKA Keratoconus Symposium in May.

Current, Relevant, Useful 2023 symposium comes to Napa Valley, California.

Learn about the second annual CRU Eye Symposium, the intentions behind the meeting, and what to expect.

Co-founder of the International Keratoconus Academy S. Barry Eiden, OD, FAAO, FSLS, gives us the inside scoop on the inaugural IKA Keratoconus Symposium, which takes place this weekend in Scottsdale, Arizona.

CEO and cofounder of the International Keratoconus Academy S. Barry Eiden, OD, FAAO, FSLS, sits down to discuss the inaugural symposium, which will be held April 22-23, 2023, in Scottsdale, Arizona.

Over the years, IKA has become an invaluable resource for eye care professionals.

Expert eye care specialists comment on the use of aceclidine as a selective miotic for the treatment of presbyopia.

Andrew S. Morgenstern discusses the selectivity of miotic agents in isolating the pupil while limiting adverse events for the management of presbyopia.

Francis S. Mah, MD, reviews miotic agents that are available or under investigation for the treatment of presbyopia.

Andrew S. Morgenstern, OD, FAAO, FNAP, highlights the importance of reducing pupil size to a certain level to optimize near vision for patients with presbyopia.

Expert eye care specialists discuss the role of miotic agents in targeting presbyopia in patients.

Stephanie Woo, OD, FAAO, FSLS, and S. Barry Eiden, OD, FAAO, discuss the Keratoconus Essentials Program, a joint effort between Woo University and the International Keratoconus Academy.

Drs Andrew S. Morgenstern and Francis S. Mah provide insight on the functionality of ocular accommodation as an autofocus lens and how this is affected in patients with presbyopia.

Francis S. Mah, MD, and Andrew S. Morgenstern, OD, FAAO, FNAP, review the impact of presbyopia on quality of life as well as current treatment options and unmet needs for disease management.